Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 1.00 |
| ▸ | MAPT | P10636 | 8/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 1.00 |
| ▸ | HPGD | P15428 | 7/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 7/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 1.00 |
| ▸ | MEN1 | O00255 | 6/20 | 1.00 |
| ▸ | BLM | P54132 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 5/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 5/20 | 1.00 |
| ▸ | DNM1 | Q05193 | 5/20 | 1.00 |
| ▸ | RECQL | P46063 | 4/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 4/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 4/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tyrphostin 47 SCHEMBL5802738 | 1.00 | EGFR (1.00) | EGFRALDH1A1MAPTKDM4EHPGD | |
| Tyrphostin 47 SCHEMBL6055056 | 1.00 | EGFR (1.00) | EGFRALDH1A1MAPTKDM4EHPGD | |
| Tyrphostin 47 SCHEMBL29378969 | 1.00 | EGFR (1.00) | EGFRALDH1A1MAPTKDM4EHPGD | |
| Tyrphostin 47 SCHEMBL5802735 | 1.00 | EGFR (1.00) | EGFRALDH1A1MAPTKDM4EHPGD | |
| Tyrphostin 47 SCHEMBL29422960 | 1.00 | EGFR (1.00) | EGFRALDH1A1MAPTKDM4EHPGD | |
| Tyrphostin 47 SCHEMBL5800282 | 1.00 | EGFR (1.00) | EGFRALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL13060220 | 0.86 | EGFR (0.77) | EGFRALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL6285299 | 0.83 | EGFR (1.00) | EGFRALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL1705642 | 0.83 | EGFR (1.00) | EGFRALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL7908162 | 0.83 | EGFR (0.71) | EGFRALDH1A1MAPTKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| EP-3319965-B1 | NOVEL COMPOUNDS FOR USE IN TREATING OR PREVENTING CANCEROUS DISEASES | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS (GR) | 2022-05-04 | — | — | EP | claimed |
| CN-113272294-A | 2, 6-bis (((1H-benzo [ D ] imidazol-2-yl) thio) methyl) pyridine and N2, N6-dibenzylpyridine-2, 6-dicarboxamide derivatives and related compounds as phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer | 雅典学院生物医学研究基金会 | 2021-08-17 | — | — | CN | claimed |
| US-20210246120-A1 | METHOD OF PREPARATION AND USE OF PHOSPHOINOSITIDE 3-KINASE INHIBITORS IN TREATING CANCER | FOUNDATION FOR RESEARCH AND TECHNOLOGY HELLAS (FORTH) (GR) | 2021-08-12 | — | — | US | claimed |
| EP-3841097-A1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | Biomedical Research Foundation of the Academy of Athens (GR) | 2021-06-30 | — | — | EP | claimed |
| WO-2020039097-A1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RESEARCH FOUNDATION OF THE ACADEMY OF ATHENS (BRFAA) (GR) | 2020-02-27 | — | — | WO | claimed |
| US-10287294-B2 | Compounds for use in treating or preventing cancerous diseases | BIOMEDICAL RESEARCH FOUNDATION OF THE ACADEMY OF ATHENS (GR) | 2019-05-14 | — | — | US | claimed |
| US-20180208597-A1 | NOVEL COMPOUNDS FOR USE IN TREATING OR PREVENTING CANCEROUS DISEASES | BIOMEDICAL RESEARCH FOUNDATION OF THE ACADEMY OF ATHENS (GR) | 2018-07-26 | — | — | US | claimed |
| EP-3319965-A1 | NOVEL COMPOUNDS FOR USE IN TREATING OR PREVENTING CANCEROUS DISEASES | Biomedical Research Foundation of the Academy of Athens (GR) | 2018-05-16 | — | — | EP | claimed |
| WO-2017005919-A1 | NOVEL COMPOUNDS FOR USE IN TREATING OR PREVENTING CANCEROUS DISEASES | BIOMEDICAL RESEARCH FOUNDATION OF THE ACADEMY OF ATHENS (GR) | 2017-01-12 | — | — | WO | claimed |
| EP-1156775-B1 | REDUCTION OF HAIR GROWTH | GILLETTE CO (US) | 2006-05-17 | — | — | EP | claimed |
| EP-1482983-A2 | NON-MYELOABLATIVE TOLEROGENIC TREATMENT WITH TYRPHOSTINS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2004-12-08 | — | — | EP | claimed |
| US-20040197335-A1 | Non-myeloablative tolerogenic treatment with tyrphostins | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2004-10-07 | — | — | US | claimed |
| WO-2003065971-A9 | NON-MYELOABLATIVE TOLEROGENIC TREATMENT WITH TYRPHOSTINS | YISSUM RES DEV CO (IL) | 2003-11-20 | — | — | WO | claimed |
| WO-2003065971-A2 | NON-MYELOABLATIVE TOLEROGENIC TREATMENT WITH TYRPHOSTINS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2003-08-14 | — | — | WO | claimed |
| EP-1156775-A1 | REDUCTION OF HAIR GROWTH | THE GILLETTE COMPANY (US) | 2001-11-28 | — | — | EP | claimed |
| US-6121269-A | TOPICALLY APPLYING A PROTEIN-TYROSINE KINASE INHIBITOR TO SKIN TO REDUCE ANDROGEN-STIMULATED HAIR GROWTH WITHOUT SIDE EFFECTS | GILLETTE COMPANY, THE, A DELAWARE CORPORATION | 2000-09-19 | — | — | US | claimed |
| WO-2000050002-A1 | REDUCTION OF HAIR GROWTH | THE GILLETTE COMPANY (US) | 2000-08-31 | — | — | WO | claimed |
| EP-0614661-A2 | Benzylidene- and cinnamylidine-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1994-09-14 | — | — | EP | claimed |
| EP-0322738-A2 | Benzylidene-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1989-07-05 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210246120-A1 | METHOD OF PREPARATION AND USE OF PHOSPHOINOSITIDE 3-KINASE INHIBITORS IN TREATING CANCER | PIK3R3, PIK3CA, PIK3C2A | EGFR 675/4885ALDH1A1 3224/4885MAPT 4764/4885 |
| US-20180208597-A1 | NOVEL COMPOUNDS FOR USE IN TREATING OR PREVENTING CANCEROUS DISEASES | BRCA1, VHL, TSG101 | EGFR 1141/4885ALDH1A1 71/4885MAPT 2960/4885 |
| US-10287294-B2 | Compounds for use in treating or preventing cancerous diseases | BRCA1, VHL, CYP27A1 | EGFR 1052/4885ALDH1A1 48/4885MAPT 2584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.